Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Ciramadol (WY 15705), a new analgesic and narcotic antagonist was studied on oral-dose form in 16 patients (15 of whom were suffering from malignant disease) to evaluate the analgesic dose and toxicity. Patients with mild or moderate pain experienced effective relief with doses of from 20 mg to 60 mg (mean dose, 47 mg). In patients with moderate to severe pain, effective pain control was not achieved (mean dose, 82 mg). There was no consistent effect on blood pressure level, heart rate, or respiratory rate. Mild or moderate sedation occurred in eight patients. Nausea and vomiting occurred in two patients.
 ...
PMID:Ciramadol. A new analgesic. 52 8

Ciramadol is a new opioid agonist-antagonist analgesic with low potential for dependency. Forty-three patients with moderate to severe chronic pain from primary or metastatic malignancy of the bone or major organs were enrolled in a randomized double-blind study that compared orally administered ciramadol (30 mg or 90 mg) to codeine (60 mg) and placebo. A single-dose, four-way crossover design, with a randomized Latin-square treatment sequence, was used. Data for 40 patients who received the above four study medications were included in the final statistical analysis of efficacy. Analgesic efficacy was measured at 0, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0, and 6.0 hours, using standard visual and verbal pain relief and pain intensity scales. All active therapies provided greater pain relief than placebo (P less than .05). Ciramadol 30 mg and codeine 60 mg demonstrated equal analgesic activity, whereas ciramadol 90 mg was superior to both therapies. The predominant adverse experiences associated with ciramadol were nausea and drowsiness, which were apparently not dose related. Ciramadol appears to be an effective analgesic at the doses tested, with tolerable gastrointestinal central nervous system side effects at both the 30-and 90-mg dose levels.
 ...
PMID:Comparison of the analgesic efficacy and safety oral ciramadol, codeine, and placebo in patients with chronic cancer pain. 368 May 68

Ciramadol, a new synthetic narcotic agonist-antagonist analgesic, was compared in 30 and 60 mg doses with pentazocine 50 mg, aspirin 650 mg, and placebo in the treatment of 153 patients with postoperative pain. All drugs were administered between six and 72 hours after surgery. Analgesic efficacy was assessed for six hours after study drug administration using verbal pain intensity, analog pain intensity, and verbal pain relief scales. Significantly (P less than .05) higher analgesic efficacy scores were seen with ciramadol 30 mg than with pentazocine 50 mg and placebo at most of the evaluation points. Doses of ciramadol 30 mg were significantly (P less than .05) more effective than aspirin 650 mg at several time periods, and ciramadol 60 mg was better than pentazocine and placebo at several evaluation times. The 30-mg dose of ciramadol was generally more effective than the 60-mg dose. The mean six-hour cumulative sum of pain intensity difference scores, total pain relief scores, and sum of pain analog intensity difference scores showed that the best analgesic response occurred in the ciramadol 30 mg group, followed by the ciramadol 60 mg, aspirin 650 mg, pentazocine 50 mg, and placebo groups. Side effects were rare and mild. There were no medically important changes in vital signs in any treatment group.
 ...
PMID:Oral ciramadol: a new analgesic for postoperative pain. 375 88

Ciramadol, an agonist-antagonist analgesic (in intramuscular doses of 30 and 60 mg) was compared with 10 mg of morphine and placebo in a double-blind, parallel study in 160 patients with postoperative pain. The patients were assigned randomly to one of the four treatment groups and could receive a dose of the medication every 3 hr as needed for 48 hr; a maximum of six doses was allowed in a 24-hr period. Formal efficacy assessments using standard pain intensity and pain relief scales were restricted to the initial dose period. The three active therapy groups had significantly (P less than 0.05) higher analgesia scores than the placebo group on all efficacy scales. The mean cumulative efficacy scores for the initial dose evaluation were highest for 60 mg of ciramadol; however, patients' overall evaluations of therapy were highest in the morphine group. Nausea and vomiting were the most frequent adverse experiences (15-25% incidence); however, there were no statistically significant differences between groups in their occurrence. A greater percentage (P less than 0.05) of patients reported skin reactions in the 60 mg ciramadol group (15%) than in the 30 mg ciramadol (0%) and placebo (0%) groups. Sedation was slightly higher with the active therapies than with placebo. Changes in vital signs were minimal. It is concluded that 60 mg of ciramadol compares favorably with 10 mg of morphine as a postoperative analgesic.
 ...
PMID:A double-blind comparison of multiple intramuscular doses of ciramadol, morphine, and placebo for the treatment of postoperative pain. 390 21

Ciramadol, a new analgesic with mixed narcotic agonist-antagonist actions, was compared with codeine and placebo in a double-blind study in 343 patients with postoperative pain. The patients received a single oral dose of either 30 or 60 mg of ciramadol, 60 mg of codeine, or placebo. As indicated by three efficacy measures (verbal and visual analog pain scores and pain relief scores), the three active treatments were superior to placebo in relieving pain, and 30 and 60 mg of ciramadol generally were equivalent and superior, respectively, to 60 mg of codeine. The group who took 60 mg of ciramadol had a significantly (P less than .05) lower cumulative remedication frequency than that for the other three groups and the highest proportion of satisfactory evaluations by patients and physicians. There was no statistically significant difference in the incidence of side effects (4% to 11%) among the treatment groups. Demonstrated safety and efficacy suggest a role for ciramadol in the treatment of postoperative pain.
 ...
PMID:A double-blind comparison of orally administered ciramadol and codeine for relief of postoperative pain. 390

A randomized double-blind trial was carried out in 54 women to evaluate the effectiveness of ciramadol in a single (60 or 30 mg) oral dose regimen, compared with 60 mg codeine and placebo, in the treatment of post-episiotomy pain. Ciramadol gave a significantly better analgesic effect, at both 2 and 6 hours, and produced negligible side-effects. Codeine did less well than placebo in this study.
 ...
PMID:A double-blind trial of single-dose ciramadol for the treatment of post-episiotomy pain. 635 2

One hundred and eighty patients (American Society of Anesthesiologists rating 1-2) received one of three oral analgesics--ciramadol (Wy. 15705) 20 mg, ciramadol 60 mg or codeine 60 mg--on a double-blind random basis for the relief of pain 24-48 hours after major general surgical, gynaecological or orthopaedic operations. All three analgesics proved equally effective and caused mild sedation only. No patient showed signs of clinical cardiorespiratory depression, and other side-effects were infrequent. Ciramadol may therefore prove a useful clinical alternative to conventional oral analgesics provided its lack of respiratory depressant properties and addiction potential in monkeys can be substantiated in humans.
 ...
PMID:Ciramadol--a new synthetic analgesic. A double-blind comparison with oral codeine for postoperative pain relief. 635 86

Ciramadol, 20, 40, or 60 mg, or a placebo was administered orally, double blind, to patients complaining of moderate (N = 89) or severe (N = 80) postoperative pain to determine the lowest effective dose. The highest dose used for moderate pain, 40 mg, was statistically more effective than placebo as measured by pain intensity differences and pain relief scores. The highest dose used to treat severe pain, 60 mg, was also more effective statistically than placebo and the lower doses of ciramadol at certain points during the 6-hour observation period. Drowsiness was minimal, and side effects were infrequent and mild in intensity. We conclude that 40 mg ciramadol for moderate postoperative pain and 60 mg ciramadol for severe postoperative pain would be the minimal oral doses to compare with standard analgesics in future studies.
 ...
PMID:Comparison of three doses of oral ciramadol and placebo for the treatment of moderate to severe postoperative pain. 675 81

The efficacy and safety of oral ciramadol, a synthetic partial agonist-antagonist analgesic, in rapid control of postoperative pain was compared with oral pentazocine in a double blind study in 46 patients. Ciramadol 20 mg and 60 mg and pentazocine 50 mg had a rapid analgesic effect, peaking within one hour. Although a similar pattern of activity was observed for ciramadol 20 mg and pentazocine 50 mg, ciramadol 60 mg provided significantly better and longer lasting pain relief (P less than 0.02). Side effects included sedation and sweating, which occurred with a similar frequency in the various treatment groups. Oral ciramadol appears to be a safe and highly effective analgesic.
 ...
PMID:Double-blind comparison of the analgesic response to oral ciramadol (WY-15.705) and pentazocine in post-operative pain. 702 54